ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,328.95
0.53%
Dow Jones
42,581.10
0.96%
Gold vs US Dollar
2,654.865
-0.66%
Brent Oil
71.215
0.37%
Bitcoin
66,270.17
1.67%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) News

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LXRX
DateTimeSourceHeadlineSymbolCompany
27/09/202413:00GlobeNewswire Inc.Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical CongressNASDAQ:LXRXLexicon Pharmaceuticals Inc
16/09/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals Announces Departure of President and Chief Operating OfficerNASDAQ:LXRXLexicon Pharmaceuticals Inc
16/09/202411:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
10/09/202413:00GlobeNewswire Inc.New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/09/202421:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in Upcoming September Investor ConferencesNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/09/202413:00GlobeNewswire Inc.New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes DurationNASDAQ:LXRXLexicon Pharmaceuticals Inc
16/08/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/08/202421:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
13/08/202413:30GlobeNewswire Inc.Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/08/202413:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/08/202413:39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
07/08/202413:00GlobeNewswire Inc.Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education SpecialistsNASDAQ:LXRXLexicon Pharmaceuticals Inc
02/08/202414:37Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LXRXLexicon Pharmaceuticals Inc
02/08/202412:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
01/08/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
01/08/202421:00GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/07/202422:44Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
29/07/202422:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
25/07/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
16/07/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA ResubmissionNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/07/202413:00GlobeNewswire Inc.New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202422:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202414:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202414:15GlobeNewswire Inc.Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and DirectorNASDAQ:LXRXLexicon Pharmaceuticals Inc
21/06/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
19/06/202413:00GlobeNewswire Inc.Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
18/06/202413:00GlobeNewswire Inc.Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of CardiologyNASDAQ:LXRXLexicon Pharmaceuticals Inc
14/06/202413:00GlobeNewswire Inc.Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX

Your Recent History

NASDAQ
TLSI
TriSalus Life Sciences
TSXV
AGG
African Gold
TSXV
MKO
Mako Mining
TSXV
RWR
Rockwealth Resources
BIT
P22BZ2
NLBNPIT22BZ2 20991231 35...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved